Skip to content
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Neurology

When Should I Seek a Second Opinion for RRMS Care?

At a Glance

An MS specialist can review an RRMS diagnosis or treatment when symptoms are unusual, MRI or spinal-fluid results are unclear, new attacks continue despite medication, safety decisions are complex, or pregnancy is planned. Do not delay urgent care or stop medication without a safe plan.

Seeking a second opinion for a relapsing-remitting multiple sclerosis (RRMS) diagnosis or treatment plan is a reasonable option to discuss with your care team when your symptoms do not match typical MS, test results are conflicting, you are facing complex medication choices, or you are planning a pregnancy. Because there is no single test that definitively proves you have MS, an MS specialist (a neurologist with advanced training in immune conditions of the brain and spinal cord) can help evaluate whether you meet the accepted diagnostic criteria and discuss appropriate treatment options [1]. However, balancing a second opinion with the risk of delaying care is important if your disease is highly active [2].

When to Question the Diagnosis

An MS diagnosis requires meeting specific standards (the McDonald criteria) that prove your symptoms and MRI lesions are separated in time and space, while also ruling out other explanations [3]. Many other conditions, called MS mimics, can cause similar symptoms [4][5]. You might consider a second opinion to review your diagnosis if:

  • Your symptoms are atypical: A typical MS relapse usually develops over hours or days, lasts at least 24 hours (in the absence of fever or infection), and can take weeks to improve [6]. If your symptoms continuously worsen over weeks without any period of recovery, this atypical presentation warrants an expert review [4]. Note: Sudden stroke-like symptoms, inability to walk, or severe new vision loss require urgent medical assessment from your treating team or an emergency room, not waiting for a second opinion.
  • Your MRI results are unusual: If your magnetic resonance imaging (MRI) scans show a tumefactive lesion (a large, mass-like spot that can resemble a tumor) or lesions that do not match classic MS patterns, a specialist should review your scans to consider other causes [7][4].
  • Your tests are conflicting: A lumbar puncture (spinal tap) that checks your cerebrospinal fluid for oligoclonal bands (inflammatory proteins) can support an MS diagnosis, but it is not 100% specific to MS and is not always required for every patient [8]. Similarly, a normal spinal tap does not automatically rule out MS [3]. A specialist can help interpret ambiguous results or run specific blood work to evaluate alternative diseases [9].

It is also important to distinguish a true relapse from a pseudo-relapse, which is a temporary worsening of old symptoms triggered by heat, stress, or infection, and does not indicate new disease activity.

When to Review Your Treatment Plan

The choices for disease-modifying therapies (DMTs)—medications that reduce relapses and new inflammatory lesions—are highly individualized. A second opinion can be helpful when:

  • You have highly active disease: If you are having frequent relapses or a rapid accumulation of new MRI lesions, early use of a high-efficacy DMT may be considered to help protect against accumulating damage [10][2]. A specialist can help you weigh expected benefits against risks, monitoring requirements, and your personal preferences.
  • There are complex safety concerns: Certain DMTs carry drug-specific risks, such as progressive multifocal leukoencephalopathy (PML), a rare viral brain infection [11]. This risk is not the same for all drugs and depends on factors like your John Cunningham (JC) virus antibody status and how long you take the medication [12]. A specialist can explain these precise risks and the required surveillance for the specific drug you are considering.
  • You are experiencing breakthrough disease: If you have new relapses or MRI lesions while on a DMT, an expert can evaluate whether this represents true breakthrough disease (which may prompt a medication switch) or if it is related to missed doses, a pseudo-relapse, or a drug that has not taken full effect yet [13][11].

Planning for Pregnancy and Breastfeeding

If you are planning to start a family, it is crucial to coordinate early with an MS specialist and an obstetrician. Medication safety depends heavily on the specific drug, your disease activity, and your conception and breastfeeding plans. While some DMTs might be continued in selected circumstances, others require strict contraception or a washout period (time to clear the drug from your system before trying to conceive) [14][15].

Importantly, never stop your medication without a drug-specific plan. Stopping certain treatments abruptly—particularly natalizumab or fingolimod—can cause a dangerous “rebound” effect, triggering severe relapses [16][17]. An expert will help you balance disease control with fetal safety, and establish a postpartum plan, as the risk of relapse often increases in the first few months after delivery [18][19].

What to Bring to Your Appointment

To get the most out of a second opinion, your new doctor needs access to the raw data and your full medical history:

  • Original MRI files: Request your original image files in a format the specialist accepts (like a disc, USB, or secure portal transfer), along with all written reports with dates for past brain and spinal cord scans [20][21].
  • Lab and medical records: Bring your complete spinal fluid report (not just the oligoclonal band result) and any blood work used to rule out mimics [8][22].
  • Your clinical timeline: Provide notes detailing your medication history (including last doses and side effects), vaccination/infection history, and when specific symptoms started and stopped.

Balancing a Second Opinion with the Need for Treatment

Uncertainty is stressful, and a second opinion is a powerful tool for shared decision-making. However, if your disease is highly active, you must balance the time it takes to see another expert with the risks of delaying care [23]. While many relapses improve substantially or completely, uncontrolled inflammation can accumulate damage over time [24]. If you have severe, frequent attacks, talk to your current treating team about a safe interim plan or how to expedite a specialist review so you do not experience unnecessary treatment gaps [25].

Common questions in this guide

When should I ask for a second opinion about an RRMS diagnosis?
A second opinion is reasonable when your symptoms do not follow a typical relapse pattern, your MRI scans show unusual lesions, or your spinal-fluid and blood-test results are unclear or conflicting. An MS specialist can review your records, apply accepted MS diagnostic criteria, and consider other conditions that can mimic MS. Sudden stroke-like symptoms, inability to walk, or severe new vision loss need urgent assessment rather than a delayed second opinion.
Can an MS specialist confirm or challenge my diagnosis?
There is no single test that proves MS. A specialist compares your symptoms, MRI scans, spinal-fluid results, and blood tests with accepted diagnostic standards while checking for conditions that mimic MS. The review may confirm the diagnosis, identify a reason for uncertainty, or suggest further testing.
Should I get a second opinion if my MS medication is not working?
Contact your current MS team promptly if you have new relapses or MRI lesions while taking a disease-modifying therapy. A specialist can assess whether this is true breakthrough disease, missed doses, temporary worsening from heat or infection, or a treatment that has not reached full effect. The result may support continuing, monitoring, or switching medication.
Is it safe to wait for a second opinion when RRMS is highly active?
Waiting can be risky when relapses are frequent or new MRI lesions are accumulating, because uncontrolled inflammation can cause lasting damage. Ask your current treating team whether you need an interim plan or an expedited specialist appointment. Sudden severe symptoms need urgent medical assessment rather than waiting.
How should I handle MS treatment if I am planning pregnancy?
Arrange an early discussion with an MS specialist and obstetrician because medication safety depends on the specific drug, disease activity, conception timing, and breastfeeding plans. Some medicines may require contraception or a washout period, while stopping certain medicines suddenly can trigger a severe rebound relapse. Do not stop or change treatment without a drug-specific plan.
What records should I bring to an MS second-opinion visit?
Bring the original MRI image files, dated written reports, the complete spinal-fluid report, blood tests used to check for other conditions, and a timeline of symptoms and treatments. Include medication doses, missed doses, side effects, vaccination or infection history, and your last dose. These details help the specialist compare disease activity and treatment response.

Get notified when new evidence is published on relapsing-remitting multiple sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (25)
  1. 1

    Intravascular lymphoma mimicking multiple sclerosis.

    Kloc G, Budziak M, Więckiewicz A, et al.

    Neurologia i neurochirurgia polska 2016; (50(4)):313-7.

    PMID: 27375151
  2. 2

    Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?

    Fernández Ó

    Multiple sclerosis and related disorders 2017; (17()):75-83 doi:10.1016/j.msard.2017.07.003.

    PMID: 29055479
  3. 3

    Multiple sclerosis - etiology and diagnostic potential.

    Kamińska J, Koper OM, Piechal K, Kemona H

    Postepy higieny i medycyny doswiadczalnej (Online) 2017; (71(0)):551-563 doi:10.5604/01.3001.0010.3836.

    PMID: 28665284
  4. 4

    Systemic Lymphoma Masquerading as Multiple Sclerosis Relapse.

    Blackbourn LW, Franada TS, Bach SE

    Cureus 2023; (15(11)):e48432 doi:10.7759/cureus.48432.

    PMID: 38073927
  5. 5

    Clinical practice patterns in multiple sclerosis management: Mexican consensus recommendations.

    Skromne-Eisenberg E, Treviño-Frenk I, Llamosa García Velázquez GL, et al.

    Multiple sclerosis and related disorders 2021; (53()):103053 doi:10.1016/j.msard.2021.103053.

    PMID: 34139461
  6. 6

    Diagnosis and Treatment of Multiple Sclerosis: A Review.

    McGinley MP, Goldschmidt CH, Rae-Grant AD

    JAMA 2021; (325(8)):765-779 doi:10.1001/jama.2020.26858.

    PMID: 33620411
  7. 7

    Tumefactive demyelinating lesions: A comprehensive review.

    Algahtani H, Shirah B, Alassiri A

    Multiple sclerosis and related disorders 2017; (14()):72-79 doi:10.1016/j.msard.2017.04.003.

    PMID: 28619436
  8. 8

    [Cerebrospinal fluid diagnostics in multiple sclerosis].

    Ruprecht K, Tumani H

    Der Nervenarzt 2016; (87(12)):1282-1287 doi:10.1007/s00115-016-0220-z.

    PMID: 27649986
  9. 9

    Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis.

    Cagol A, Cortese R, Barakovic M, et al.

    JAMA neurology 2024; (81(2)):143-153 doi:10.1001/jamaneurol.2023.4737.

    PMID: 38079177
  10. 10

    Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?

    Edan G, Le Page E

    Drugs 2023; (83(15)):1351-1363 doi:10.1007/s40265-023-01942-0.

    PMID: 37725259
  11. 11

    Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

    Rae-Grant A, Day GS, Marrie RA, et al.

    Neurology 2018; (90(17)):777-788 doi:10.1212/WNL.0000000000005347.

    PMID: 29686116
  12. 12

    First-Line Use of Higher-Efficacy Disease-Modifying Therapies in Multiple Sclerosis: Canadian Consensus Recommendations.

    Freedman MS, Clift F, Devonshire V, et al.

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2025; 1-10 doi:10.1017/cjn.2025.10342.

    PMID: 40485478
  13. 13

    Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.

    Chalmer TA, Kalincik T, Laursen B, et al.

    Journal of neurology 2019; (266(2)):306-315 doi:10.1007/s00415-018-9126-y.

    PMID: 30515628
  14. 14

    The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.

    Webb EJD, Meads D, Eskytė I, et al.

    The patient 2020; (13(5)):583-597 doi:10.1007/s40271-020-00429-4.

    PMID: 32588337
  15. 15

    Building Towards Initiation, Moderation, De-Escalation and Cessation of Disease-Modifying Treatments for Multiple Sclerosis in Greece: An Expert Panel Consensus Meeting.

    Boziki MK, Bakirtzis C, Alexopoulos H, et al.

    Brain sciences 2026; (16(6)) doi:10.3390/brainsci16060580.

    PMID: 42352589
  16. 16

    Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.

    Villaverde-González R

    Degenerative neurological and neuromuscular disease 2022; (12()):1-21 doi:10.2147/DNND.S203406.

    PMID: 35023987
  17. 17

    Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era.

    Alroughani R, Alowayesh MS, Ahmed SF, et al.

    Neurology 2018; (90(10)):e840-e846 doi:10.1212/WNL.0000000000005065.

    PMID: 29429970
  18. 18

    Neuroimmunological Disorders: The Gender Effect.

    Graham EL

    Neurologic clinics 2023; (41(2)):315-330 doi:10.1016/j.ncl.2022.10.004.

    PMID: 37030960
  19. 19

    Family planning considerations in people with multiple sclerosis.

    Krysko KM, Dobson R, Alroughani R, et al.

    The Lancet. Neurology 2023; (22(4)):350-366 doi:10.1016/S1474-4422(22)00426-4.

    PMID: 36931808
  20. 20

    2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.

    Wattjes MP, Ciccarelli O, Reich DS, et al.

    The Lancet. Neurology 2021; (20(8)):653-670 doi:10.1016/S1474-4422(21)00095-8.

    PMID: 34139157
  21. 21

    Magnetic Resonance Imaging in Multiple Sclerosis: An Analysis of the Implementation of the Portuguese Consensus.

    Cordeiro A, Marques AJ, Castro AR, et al.

    Acta medica portuguesa 2025; (38(8)):446-459 doi:10.20344/amp.22637.

    PMID: 40614047
  22. 22

    Diagnosis of multiple sclerosis: progress and challenges.

    Brownlee WJ, Hardy TA, Fazekas F, Miller DH

    Lancet (London, England) 2017; (389(10076)):1336-1346 doi:10.1016/S0140-6736(16)30959-X.

    PMID: 27889190
  23. 23

    Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the 'suboptimal therapy' patient population.

    Chappell M, Sanderson A, Arun T, et al.

    Journal of the neurological sciences 2024; (464()):123172 doi:10.1016/j.jns.2024.123172.

    PMID: 39142083
  24. 24

    How patients with multiple sclerosis acquire disability.

    Lublin FD, Häring DA, Ganjgahi H, et al.

    Brain : a journal of neurology 2022; (145(9)):3147-3161 doi:10.1093/brain/awac016.

    PMID: 35104840
  25. 25

    Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review.

    Merkel B, Butzkueven H, Traboulsee AL, et al.

    Autoimmunity reviews 2017; (16(6)):658-665 doi:10.1016/j.autrev.2017.04.010.

    PMID: 28428119

This page is for informational purposes only and does not constitute medical advice about your RRMS diagnosis or treatment. Do not stop or change an MS medication without a drug-specific plan from your healthcare team, especially when planning pregnancy.